EP News: Case Reports

  • T. Jared Bunch
    Address reprint requests and correspondence: Dr T. Jared Bunch, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah School of Medicine, 30 N 1900 E, Room 4A100, Salt Lake City, UT 84132.
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah
    Search for articles by this author
Published:September 02, 2022DOI:
      Catheter ablation for atrial fibrillation (AF) is more effective than drug therapy. In patients with persistent and long-standing persistent AF, additional ablation is often required that can compromise mechanical function that can lead to long-term morbidity. Ali et al ( shared a case of a 72-year-old man with a history of 3 prior ablation procedures for symptomatic AF, including multiple linear ablation procedures in addition to pulmonary vein isolation. Three years after after his last ablation he presented with recurrent atrial tachycardia on sotalol 80 mg twice daily and rivaroxaban 20 mg daily. He was referred for repeat electrophysiology study and attempted ablation. A transesophageal echocardiogram identified multiple mobile masses consistent with thrombi in the left atrium, with one measuring 1.5 cm between the appendage and the left superior pulmonary vein. The attempted ablation procedure was aborted, and anticoagulation was switched to warfarin. Three months later, the thrombi persisted and he was switched to enoxaparin. Three months later, the thrombi remained and he was transitioned back to rivoraxaban. Serum testing for a hypercoagulable state was unremarkable. These data highlight important risks with extensive ablation that compromise mechanical function.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect